The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. Danazol may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. Metolazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The metabolism of Paricalcitol can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Ouabain. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. Quinethazone may increase the hypercalcemic activities of Paricalcitol. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The metabolism of Paricalcitol can be increased when combined with Rifampicin. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Primidone. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The metabolism of Paricalcitol can be decreased when combined with Isradipine. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). Indapamide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab.